Online citations, reference lists, and bibliographies.
← Back to Search

Cyclosporine A Delivery To The Eye: A Pharmaceutical Challenge.

F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Béhar-Cohen, R. Gurny
Published 2003 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Systemic administration of cyclosporine A (CsA) is commonly used in the treatment of local ophthalmic conditions involving cytokines, such as corneal graft rejection, autoimmune uveitis and dry eye syndrome. Local administration is expected to avoid the various side effects associated with systemic delivery. However, the currently available systems using oils to deliver CsA topically are poorly tolerated and provide a low bioavailability. These difficulties may be overcome through formulations aimed at improving CsA water solubility (e.g. cyclodextrins), or those designed to facilitate tissue drug penetration using penetration enhancers. The use of colloidal carriers (micelles, emulsions, liposomes and nanoparticles) as well as the approach using hydrosoluble prodrugs of CsA have shown promising results. Solid devices such as shields and particles of collagen have been investigated to enhance retention time on the eye surface. Some of these topical formulations have shown efficacy in the treatment of extraocular diseases but were inefficient at reaching intraocular targets. Microspheres, implants and liposomes have been developed to be directly administered subconjunctivally or intravitreally in order to enhance CsA concentration in the vitreous. Although progress has been made, there is still room for improvement in CsA ocular application, as none of these formulations is ideal.
This paper references
10.1023/A:1010928025753
The Mucosal Toxicity of Different Benzalkonium Chloride Analogues Evaluated with an Alternative Test Using Slugs
E. Adriaens (2004)
10.1016/S0378-5173(01)00760-8
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
A. M. de Campos (2001)
10.1111/j.2042-7158.1996.tb03911.x
Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers
P. Calvo (1996)
10.1076/CEYR.17.1.39.5251
Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat.
J. R. Juberías (1998)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
Ocular penetration of cyclosporin A. The rabbit eye.
D. Benezra (1990)
10.3928/1542-8877-19860301-06
Retinal toxicity study of intravitreal cyclosporin.
J. Grisolano (1986)
10.1097/00003226-200203000-00006
Topical Cyclosporin A in the Management of Therapeutic Keratoplasty for Mycotic Keratitis
H. Perry (2002)
Handbook of Pharmaceutical Excipients
R. C. Rowe (1994)
10.1016/S0165-2427(00)00219-1
Effect of an intravitreal cyclosporine implant on experimental uveitis in horses.
B. Gilger (2000)
10.1001/ARCHOPHT.1992.01080140044023
Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device.
G. Sanborn (1992)
10.1089/JOP.1991.7.221
Cyclosporine: a therapy in inflammatory eye disease.
D. Wakefield (1991)
10.1007/BF00137134
Liposome-bound cyclosporine: Retinal toxicity after intravitreal injection
A. Alghadyan (2004)
10.1016/S0939-6411(98)00069-1
Ocular tolerance of preservatives on the murine cornea.
P. Furrer (1999)
10.3109/02652049709033830
Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study.
C. L. Le Bourlais (1997)
Improved extemporaneous formulation of cyclosporine ophthalmic drops.
D. Mueller (1994)
10.3109/02713689508998493
A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy.
A. Apel (1995)
10.1136/bjo.83.11.1225
New developments in sustained release drug delivery for the treatment of intraocular disease
G. Vélez (1999)
10.1016/S0378-5173(00)00443-9
Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability.
M. Sznitowska (2000)
10.1016/S0378-5173(99)00003-4
Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention.
O. Felt (1999)
10.1023/A:1016062224568
Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration
S. D. Mithani (2004)
10.1046/J.1463-5224.2000.00117.X
Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A.
B. Gilger (2000)
Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs
Morgan Rv (1991)
Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer.
C. C. Lai (2000)
10.2165/00003495-199550050-00009
Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
S. Noble (1995)
10.1089/JOP.1991.7.301
Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers.
S. Solch (1991)
10.1076/CEYR.18.2.91.5381
Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.
A. Acheampong (1999)
10.1034/J.1600-0420.2002.800205.X
Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.
T. Loftsson (2002)
Intraocular penetration of topically applied cyclosporine.
Kaswan Rl (1988)
10.1001/ARCHOPHT.1981.03930020514024
Suppression of corneal allograft rejection by cyclosporin A.
J. Salisbury (1981)
10.1023/A:1013671819604
Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits
M. Kuwano (2004)
10.3109/02652049109021873
Studies on the transport pathway of PBCA nanoparticles in ocular tissues.
A. Zimmer (1991)
10.1097/00003226-199007000-00003
The collagen shield. A new vehicle for delivery of cyclosporin A to the eye.
J. Reidy (1990)
10.1001/ARCHOPHT.1996.01100130307014
Evaluation of a delivery system providing long-term release of cyclosporine.
P. A. Pearson (1996)
10.1016/S0161-6420(93)31558-7
Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye.
J. K. Milani (1993)
10.1007/s004170050321
Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit
Maria Victoria de Rojas Silva (1999)
10.1016/S0168-3659(99)00192-3
Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
S. Law (2000)
The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops.
A. Kanai (1989)
10.1007/BF00137135
Liposome-bound cyclosporine: Clearance after intravitreal injection
A. Alghadyan (2004)
Pharmacokinetic of topical cyclosporin A in the rabbit eye.
M. Wiederholt (1986)
10.1007/s004170050257
Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study
A. Heiligenhaus (1999)
10.1111/j.1755-3768.1994.tb02792.x
Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome
K. Gündüz (1994)
10.1023/A:1016015803611
Polyester Nanocapsules as New Topical Ocular Delivery Systems for Cyclosporin A
P. Calvo (2004)
10.1016/S0161-6420(96)30636-2
Longitudinal tear study after cyclosporine in kidney transplant recipients.
S. L. Palmer (1996)
10.1097/00003226-200110000-00015
Prolongation of Corneal Allograft Survival Using Cyclosporine in a Polylactide-co-glycolide Polymer
L. Xie (2001)
10.1021/JM00076A002
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
N. El Tayar (1993)
10.3109/02713689409167297
Local efficacy of cyclosporine in corneal transplant therapy.
C. Oh (1994)
10.1016/S0002-9394(14)76692-9
Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.
R. Nussenblatt (1991)
10.1089/JOP.1995.11.319
Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine.
B. Gebhardt (1995)
10.1007/BF00137133
Liposome-bound cyclosporine: Aqueous and vitreous level after subconjunctival injection
A. Alghadyan (2004)
10.1002/JPS.2600830120
Effects of four penetration enhancers on corneal permeability of drugs in vitro.
D. Tang-Liu (1994)
10.1016/S0168-3659(01)00441-2
Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs.
S. Kawakami (2001)
10.1097/00007691-198406000-00002
Cyclosporine: experience with therapeutic monitoring.
L. Bowers (1984)
10.3109/02713689609000766
An intravitreal device providing sustained release of cyclosporine and dexamethasone.
L. Enyedi (1996)
Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A
M. Abdulrazik (2001)
10.1007/s003470050146
Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten Risikofaktor
T. Reinhard (1997)
10.1016/S0161-6420(00)00035-X
Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆
D. Stevenson (2000)
10.1136/bjo.74.6.350
Ocular penetration of cyclosporin A. III: The human eye.
D. Benezra (1990)
10.1001/ARCHOPHT.120.3.330
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.
K. S. Kunert (2002)
10.1034/J.1600-0420.1999.770217.X
Toxicological evaluation of cyclosporine eyedrops.
S. K. Knagenhjelm (1999)
The side-effects of ciclosporine-A and tacrolimus.
M. Mihatsch (1998)
10.1002/(SICI)1097-4636(1999)48:2<111::AID-JBM3>3.0.CO;2-W
Effects of dry heat and saturated steam on the physical properties of chitosan.
L. Y. Lim (1999)
10.3109/02713689209000737
Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea.
L. Cheeks (1992)
10.1007/s00467-001-0810-1
Cyclosporin-related nephrotoxicity in children with nephrotic syndrome
V. Ganesan (2001)
10.1159/000063299
Colchicine Suppresses Osteopontin Expression and Inflammatory Cell Infiltration in Chronic Cyclosporine Nephrotoxicity
C. Li (2002)
10.1097/00003226-199309000-00008
Topical Cyclosporin A in the Treatment of Anterior Segment Inflammatory Disease
E. Holland (1993)
10.1038/eye.2001.10
Topical cyclosporin A in the management of vernal keratoconjunctivitis
V. Gupta (2001)
10.1081/PDT-100102035
Influence of Emulsion Droplet Surface Charge on Indomethacin Ocular Tissue Distribution
S. Klang (2000)
10.1016/0378-5173(94)90179-1
Study of the mechanism of interaction of poly(ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy
P. Calvo (1994)
10.1007/BF02230339
Relapsing Wegner's granulomatosis: Successful treatment with cyclosporin-A
C. Georganas (2005)
10.1016/S0142-9612(96)00144-5
Influence of sterilization processes on poly(ε-caprolactone) nanospheres
V. Masson (1997)
10.1016/S0002-9394(00)00625-5
Unusual corneal deposit after the topical use of cyclosporine as eyedrops.
S. Kachi (2000)
10.1016/S0002-9394(14)73872-3
Local therapy of corneal allograft rejection with cyclosporine.
J. Zhao (1995)
10.1136/bjo.73.8.600
Penetration of 2% cyclosporin eyedrops into human aqueous humour.
M. Díaz-Llopis (1989)
10.1016/S0161-6420(99)00176-1
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1
K. Sall (2000)
10.1001/ARCHOPHT.1985.01050010107030
Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum.
M. W. Mosteller (1985)
Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
D. Olivero (1991)
10.3109/02713689408995775
Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields.
U. Pleyer (1994)
10.1016/S0002-9394(14)70579-3
An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis.
A. M. El-Asrar (1996)
10.1016/S0378-5173(01)00907-3
Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation.
D. Monti (2002)
Topically applied cyclosporine in azone prolongs corneal allograft survival.
C. Newton (1988)
10.1136/VR.137.20.504
Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial
J. Sansom (1995)
Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection.
C. Herbort (1989)
10.1016/S0140-6736(65)92676-0
HYPERBARIC OXYGENATION CHRONIC OSTEOMYELITIS.
W. Slack (1965)
10.1007/BF00915740
Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits
C. A. Harper (2004)
10.1159/000267160
A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits.
S. Muchtar (1992)
10.1056/NEJM198911163212002
Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
M. Prummel (1989)
10.1016/S0161-6420(98)91176-9
Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
G. Jaffe (1998)
10.1016/S0140-6736(89)92381-7
DOUBLE-MASKED TRIAL OF CYCLOSPORIN VERSUS COLCHICINE AND LONG-TERM OPEN STUDY OF CYCLOSPORIN IN BEHÇET'S DISEASE
K. Masuda (1989)
10.1089/JOP.1994.10.509
Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits.
N. Naveh (1994)
10.1089/JOP.1995.11.509
Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection.
B. Gebhardt (1995)
10.1038/eye.1997.126
A comparative approach to topical cyclosporine therapy
D. Williams (1997)
10.1097/00003226-200107000-00013
Effects of Three Penetration Enhancers on Transcorneal Permeation of Cyclosporine
P. van der Bijl (2001)



This paper is referenced by
10.1016/J.IJPHARM.2005.05.036
Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate.
M. Yamaguchi (2005)
10.1016/S1773-2247(13)50016-5
Nano and microtechnologies for ophthalmic administration, an overview
R. Herrero-Vanrell (2013)
10.1186/s12886-019-1136-8
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
C. H. Park (2019)
OPSISPORIN : A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS Dr
D. Palmer (2016)
10.1016/J.IJPHARM.2006.07.022
Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A.
Hongzhuo Liu (2006)
10.1167/IOVS.05-1373
Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study.
Y. He (2006)
10.1167/IOVS.07-0229
Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation.
T. Said (2007)
10.1002/JPS.20898
Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of Cyclosporin A in vitro and dermal pharmacokinetics in vivo.
Hongzhuo Liu (2007)
10.1016/j.biomaterials.2017.11.046
DNA nanoparticles for ophthalmic drug delivery.
Jan Willem de Vries (2018)
10.1016/J.EJPS.2005.05.003
A water-soluble prodrug of cyclosporine A for ocular application: a stability study.
F. Lallemand (2005)
10.1016/j.jconrel.2011.01.010
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
P. Aksungur (2011)
10.1080/02713683.2018.1563702
The Efficiency of Cyclosporine A-Eluting Contact Lenses for the Treatment of Dry Eye
J. Choi (2019)
10.1080/17425247.2016.1201059
Application of lipid nanoparticles to ocular drug delivery
L. Battaglia (2016)
10.1016/J.EJPB.2004.12.003
Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer.
L. B. Lopes (2005)
10.3390/colloids4040046
Cyclosporine CsA—The Physicochemical Characterization of Liposomal and Colloidal Systems
A. Wiącek (2020)
10.1016/j.jconrel.2016.01.056
Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.
M. Guada (2016)
Doskonalenie form leku w celu osiągnięcia skutecznej farmakoterapii
A. Czech (2015)
10.1097/00130832-200410000-00014
Ocular allergy and dry eye syndrome
L. Bielory (2004)
10.1097/MJT.0b013e3181f47f3f
Recent Advances in Prodrugs as Drug Delivery Systems
C. Lin (2012)
10.7508/NMJ.2013.01.006
Evaluation of cyclosporine A eye penetration after administration of liposomal or conventional forms in animal model
S. Nikoofal-Sahlabadi (2013)
10.1590/S1516-93322005000400010
Cyclosporin A in skin samples from in vitro penetration studies may be assayed by a simple HPLC method
L. B. Lopes (2005)
10.1016/j.ijpharm.2018.05.015
Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: Design, optimization, and in vitro/ex vivo evaluation
J. Álvarez-Trabado (2018)
10.1016/j.clinthera.2018.09.012
Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
M. Labetoulle (2018)
Stability studies of intravenous cyclosporine preparations stored in non-PVC containers
Mengqing Li (2013)
Rôle pro-inflammatoire des cellules épithéliales de la conjonctive dans un modèle in vitro de sécheresse oculaire
E. Warcoin (2016)
10.1007/s10792-020-01391-8
Sustained subconjunctival drug delivery systems: current trends and future perspectives
Fojan Rafiei (2020)
10.1016/j.ijpharm.2019.05.018
Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Yang Liu (2019)
10.1016/j.ijpharm.2010.10.008
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Jie Shen (2010)
10.1016/j.pharma.2011.01.001
Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye.
C. Di Tommaso (2011)
10.1016/j.ijpharm.2011.05.035
Controlled poly(l-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycine--the effect of copolymer chain microstructure on drug release rate.
K. Jelonek (2011)
10.1021/mp500401t
Cellular uptake of coumarin-6 under microfluidic conditions into HCE-T cells from nanoscale formulations.
S. Pretor (2015)
10.1016/j.ejpb.2015.01.026
Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration.
G. Abrego (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar